Scribe Therapeutics Inc. Common Stock (SCTX) Stock
NYSE · SCTX
28.05
Fundamentals
Market cap
$624.75M
Price / Earnings ratio
-28.6x
Price / Sales ratio
12.2x
Price / Book ratio
-3.8x
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
SectorHealthcare
IndustryBiotechnology
Employees82
CEODr. Benjamin L. Oakes Ph.D.
IPO DateJul 24, 2026
HeadquartersAlameda, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Benjamin L. Oakes Ph.D. | Co-Founder, President, CEO & Chairman | 1989 |
| Mr. David L. Parrot M.B.A. | CFO & Treasurer | 1969 |
| Dr. Svetlana Lucas Ph.D. | Chief Business Officer | 1972 |
| Dr. Jennifer A. Doudna Ph.D. | Co-Founder & Scientific Advisor | 1964 |
| Mr. Brett T. Staahl Ph.D. | Co-Founder & VP of External Innovation | — |
| Mr. David F. Savage Ph.D. | Co-Founder & Scientific Advisor | — |
| Mr. Richard Hector J.D., Ph.D. | Head of Intellectual Property | — |
| Ms. Chitra Sharma M.S. | Senior Vice President of Development | — |
| Mr. Sunny Mok M.B.A., Ph.D. | Senior Vice President of Operations | — |
| Stephen V. Thau | Secretary | — |
Fundamentals
Valuation
Market cap$624.75M
Price-to-sales ratio12.21
Price-to-book value-3.79
Price-earnings ratio-28.60
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.52
Income Statement
Average volume322,327
EBITDAN/A
1 year high (52w)$39.60
1 year low (52w)$17.31
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



